Cyclic AMP Phosphodiesterase-4 in Brain Tumor Biology: Immunochemical Analysis
Central to advancing the care for patients with malignant neoplasms are efforts to delineate how cancer cells differ from their normal counterparts, and the identification of biological targets whose activity, when normalized, corrects the cancer phenotype and re-establishes normal growth control. In this regard we and others have described the tumor promoting actions of cyclic adenosine monophosphate (cAMP) phosphodiesterases and the antitumor effects of phosphodiesterase inhibitors. In the following chapter we will focus on the unique biology of the cAMP phosphodiesterase-4 (PDE4) family of cAMP hydrolases as it pertains to brain tumors and the experimental challenges that arise when studying patterns of PDE4 expression.
KeywordsPDE4 Activity DAOY Cell Normal Swine Serum PDE4 Isoforms PDE4 Family
Acknowledgements. The authors thank Nicole Warrington for critical reading of the manuscript. This work was supported by the NCI/NIH (CA118389) to JBR.
- Chen, T.C., Wadsten, P., Su, S., Rawlinson, N., Hofman, F.M., Hill, C.K., and Schonthal, A.H. (2002) The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol. Ther. 1:268–276PubMedGoogle Scholar
- Lynch, M.J., Baillie, G.S., Mohamed, A., Li, X., Maisonneuve, C., Klussmann, E., van Heeke, G., and Houslay, M.D. (2005) RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J. Biol. Chem. 280:33178–3389PubMedCrossRefGoogle Scholar
- Marko, D., Pahlke, G., Merz, K.H., and Eisenbrand, G. (2000) Cyclic 3′,5′-nucleotide phosphodiesterases: potential targets for anticancer therapy. Chem. Res. Toxicol. 13:944–948Google Scholar
- Marko, D., Romanakis, K., Zankl, H., Furstenberger, G., Steinbauer, B., and Eisenbrand, G. (1998) Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Cell Biochem. Biophys. 28:75–101PubMedCrossRefGoogle Scholar
- McCahill, A., McSorley, T., Huston, E., Hill, E.V., Lynch, M.J., Gall, I., Keryer, G., Lygren, B., Tasken, K., van Heeke, G., and Houslay, M.D. (2005) In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 17:1158–1173PubMedCrossRefGoogle Scholar
- McEwan, D.G., Brunton, V.G., Baillie, G.S., Leslie, N.R., Houslay, M.D., and Frame, M.C. (2007) Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res. 67:5248–5257PubMedCrossRefGoogle Scholar
- Merz, K.H., Marko, D., Regiert, T., Reiss, G., Frank, W., and Eisenbrand, G. (1998) Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth. J. Med. Chem. 41:4733–4743PubMedCrossRefGoogle Scholar
- Ogawa, R., Streiff, M.B., Bugayenko, A., and Kato, G.J. (2002) Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 99: 3390–3397PubMedCrossRefGoogle Scholar
- Scotland, G., and Houslay, M.D. (1995) Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase. Biochem. J. 308 (Pt 2):673–681PubMedGoogle Scholar
- Shakur, Y., Pryde, J.G., and Houslay, M.D. (1993) Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem. J. 292 (Pt 3):677–686PubMedGoogle Scholar
- Siegmund, B., Welsch, J., Loher, F., Meinhardt, G., Emmerich, B., Endres, S., and Eigler, A. (2001) Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. Leukemia 15:1564–1571PubMedCrossRefGoogle Scholar
- Warrington, N.M., Woerner, B.M., Daginakatte, G.C., Dasgupta, B., Perry, A., Gutmann, D.H., and Rubin, J.B. (2007) Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 67:8588–8595PubMedCrossRefGoogle Scholar